Laurie Keefer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laurie Keefer has a total of 249 co-authors. Here are the top co-authors by number of shared publications:
- Robert Patrick Hirten
The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, USA
7 shared publications - Matteo Danieletto
Windreich Department of AI & Human Health, Icahn School of Medicine at Mount Sinai, New York, NY
6 shared publications - Bruce E. Sands
Dr. Henry D. Janowitz Division of Gastroenterology Icahn School of Medicine at Mount Sinai New York New York USA
5 shared publications - Dennis S. Charney
Icahn School of Medicine at Mount Sinai, New York, NY, USA
5 shared publications - Drew Helmus
The Dr Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States
5 shared publications - Eddye Golden
Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, United States
5 shared publications
Latest Publications
- 31 October 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Sleep disturbance in inflammatory bowel disease: clinical associations and gaps in care
Background and aims: Sleep disturbance is highly prevalent in inflammatory bowel disease (IBD), affecting up to 70% of patients with active disease and 40% in remission, and is associated with worse clinical and patient-reported outcomes. Understanding of the multifactorial drivers of sleep disturbances in IBD remains limited, and as such, there is an absence of clear guidance for evaluating and managing sleep problems in this population. We aimed to identify factors associated with sleep disturbance and characterize patient beliefs, self-management strategies, and interest in sleep-focused testing and treatments. Methods: Adults with Crohn disease and ulcerative colitis completed a cross-sectional survey assessing disease activity, sleep quality, stress, chronotype, fatigue, and mood. A study-specific questionnaire evaluated sleep-related beliefs, behaviors, and treatment interest. Descriptive analyses characterized sleep patterns and behaviors, and multivariable regression identified factors associated with poor sleep. Results: Among 204 participants, 76.5% reported poor sleep quality and 55.9% had clinically significant sleep disturbance, which was more common in active disease than remission (80.9% vs 46.0%, P < .001). Active disease (odds ratio [OR], 4.31), higher perceived stress (OR, 1.21), and anxiety (OR, 2.63) were associated with increased odds of clinically significant sleep disturbance, while intermediate (OR, 0.16) and morning chronotypes (OR, 0.07) were associated with lower odds of clinically significant sleep disturbance compared with evening chronotypes. Most participants reported self-management behaviors related to sleep, with widespread use of sleep hygiene and over-the-counter strategies but minimal exposure to cognitive behavioral therapy for insomnia (0.5%). Interest in sleep-focused interventions was high, particularly for wearable monitoring, home-based testing, and behavioral and light-based therapies. Conclusion: Sleep disturbance in inflammatory bowel disease is common and reflects interacting inflammatory, psychological, and circadian factors. Use of evidence-based therapies remains extremely limited, highlighting a substantial gap in care.
- 31 October 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Sleep disturbance in inflammatory bowel disease: clinical associations and gaps in care
Background and aims: Sleep disturbance is highly prevalent in inflammatory bowel disease (IBD), affecting up to 70% of patients with active disease and 40% in remission, and is associated with worse clinical and patient-reported outcomes. Understanding of the multifactorial drivers of sleep disturbances in IBD remains limited, and as such, there is an absence of clear guidance for evaluating and managing sleep problems in this population. We aimed to identify factors associated with sleep disturbance and characterize patient beliefs, self-management strategies, and interest in sleep-focused testing and treatments. Methods: Adults with Crohn disease and ulcerative colitis completed a cross-sectional survey assessing disease activity, sleep quality, stress, chronotype, fatigue, and mood. A study-specific questionnaire evaluated sleep-related beliefs, behaviors, and treatment interest. Descriptive analyses characterized sleep patterns and behaviors, and multivariable regression identified factors associated with poor sleep. Results: Among 204 participants, 76.5% reported poor sleep quality and 55.9% had clinically significant sleep disturbance, which was more common in active disease than remission (80.9% vs 46.0%, P < .001). Active disease (odds ratio [OR], 4.31), higher perceived stress (OR, 1.21), and anxiety (OR, 2.63) were associated with increased odds of clinically significant sleep disturbance, while intermediate (OR, 0.16) and morning chronotypes (OR, 0.07) were associated with lower odds of clinically significant sleep disturbance compared with evening chronotypes. Most participants reported self-management behaviors related to sleep, with widespread use of sleep hygiene and over-the-counter strategies but minimal exposure to cognitive behavioral therapy for insomnia (0.5%). Interest in sleep-focused interventions was high, particularly for wearable monitoring, home-based testing, and behavioral and light-based therapies. Conclusion: Sleep disturbance in inflammatory bowel disease is common and reflects interacting inflammatory, psychological, and circadian factors. Use of evidence-based therapies remains extremely limited, highlighting a substantial gap in care.
- 25 September 2026
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
Orthostatic Intolerance in Patients With Disorders of Gut-Brain Interaction
Background: Patients with severe manifestations of disorders of gut-brain interaction (DGBI) have higher rates of concomitant Orthostatic Intolerance (OI) and Postural Orthostatic Tachycardia Syndrome (POTS). These conditions diminish quality of life and increase health care use. We conducted a systematic review to assess OI and POTS prevalence in patients with DGBI. Methods: Databases were searched through January 2026 for articles reporting the prevalence of OI and POTS among patients with DGBI. Pooled prevalence rates, odds ratios (ORs), and confidence intervals (CIs) were calculated using a random-effects model. Key Results: Thirteen studies included 869 patients with DGBI and 1951 controls. OI prevalence in DGBI patients was DGBI ( PP =50.0%, 95% CI: 35.0-64.9). The odds of OI in patients with DGBI were significantly higher compared with controls ( OR =5.17, 95% CI: 1.73-15.50, P =0.003). Pediatric patients with DGBI had a higher prevalence of OI (59.7%, 95% CI: 36.4-79.3) than adults (32.5%, 95% CI: 19.3-49.4). The prevalence of OI in patients with DGBI was significantly higher when diagnosed using the Rome IV criteria (66.1%, 95% CI: 43.3-83.3) compared with the Rome III criteria (30.6%, 95% CI: 21.4-41.6). The prevalence of OI in DGBI was higher with questionnaire-based diagnosis (54.5%, 95% CI: 9.7-93.0) compared with physician-based diagnosis (48.8%, 95% CI: 35.2-62.7). Finally, POTS was prevalent in 31.5% (95% CI: 17.3-50.2) of patients with DGBI. Conclusions: OI is more prevalent in patients with DGBI as compared with controls without DGBI. POTS occurs in over one-third of patients with DGBI. While OI and DGBI are associated, clinical heterogeneity suggests low-quality evidence, warranting cautious interpretation.
- 25 September 2026
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
Orthostatic Intolerance in Patients With Disorders of Gut-Brain Interaction
Background: Patients with severe manifestations of disorders of gut-brain interaction (DGBI) have higher rates of concomitant Orthostatic Intolerance (OI) and Postural Orthostatic Tachycardia Syndrome (POTS). These conditions diminish quality of life and increase health care use. We conducted a systematic review to assess OI and POTS prevalence in patients with DGBI. Methods: Databases were searched through January 2026 for articles reporting the prevalence of OI and POTS among patients with DGBI. Pooled prevalence rates, odds ratios (ORs), and confidence intervals (CIs) were calculated using a random-effects model. Key Results: Thirteen studies included 869 patients with DGBI and 1951 controls. OI prevalence in DGBI patients was DGBI ( PP =50.0%, 95% CI: 35.0-64.9). The odds of OI in patients with DGBI were significantly higher compared with controls ( OR =5.17, 95% CI: 1.73-15.50, P =0.003). Pediatric patients with DGBI had a higher prevalence of OI (59.7%, 95% CI: 36.4-79.3) than adults (32.5%, 95% CI: 19.3-49.4). The prevalence of OI in patients with DGBI was significantly higher when diagnosed using the Rome IV criteria (66.1%, 95% CI: 43.3-83.3) compared with the Rome III criteria (30.6%, 95% CI: 21.4-41.6). The prevalence of OI in DGBI was higher with questionnaire-based diagnosis (54.5%, 95% CI: 9.7-93.0) compared with physician-based diagnosis (48.8%, 95% CI: 35.2-62.7). Finally, POTS was prevalent in 31.5% (95% CI: 17.3-50.2) of patients with DGBI. Conclusions: OI is more prevalent in patients with DGBI as compared with controls without DGBI. POTS occurs in over one-third of patients with DGBI. While OI and DGBI are associated, clinical heterogeneity suggests low-quality evidence, warranting cautious interpretation.
- Open Access
- 23 July 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e98352
The WISH 2.0 Intervention for Irritable Bowel Syndrome: Protocol for a Pilot Randomized Controlled Trial
Background: There is a critical need for acceptable, scalable, and mechanistically targeted behavioral health interventions for irritable bowel syndrome (IBS), known as brain-gut behavior therapies (BGBTs). Although positive psychology (PP) interventions, which focus on the cultivation of positive psychological well-being, have been linked to improved health outcomes across diverse medical populations, they have not yet been investigated in IBS. To address this gap, we developed WISH (Well-Being in IBS: Strengths and Happiness), a novel, 9-week, phone-delivered PP-based BGBT for individuals with IBS. Objective: This randomized controlled trial (RCT) aims to evaluate the feasibility, acceptability, preliminary effects, and candidate gut-brain mechanisms of a 9-week phone-delivered PP intervention for IBS compared with a time- and attention-matched educational control. Methods: The WISH 2.0 trial is a parallel-group, 9-week pilot RCT that aims to enroll 50 adults meeting Rome IV criteria for IBS. Participants are randomized (1:1), stratified by IBS subtype and gender, to either the WISH 2.0 intervention or an educational control condition. Both conditions consist of 9 weekly 30-minute phone sessions accompanied by weekly manualized exercises. Primary outcomes are feasibility (proportion completing ≥6 of 9 sessions) and acceptability (weekly ease and utility ratings). Secondary outcomes include WISH 2.0’s preliminary effects on health-related, health behavior, and psychological outcomes, assessed at 4 time points: baseline, intervention midpoint, the postintervention assessment, and the 3-month postintervention assessment. Candidate gut-brain mechanisms that might underlie WISH 2.0’s effects, including changes in autonomic function (heart rate variability), interoception (self-report measure), gene expression (whole transcriptome RNA sequencing), and immune system activity (serum inflammatory biomarkers), will be explored before and after the intervention. Results: The trial was approved by the Mass General Brigham Institutional Review Board and prospectively registered at ClinicalTrials.gov in March 2025. Funding was awarded in June 2025. Following a study start-up period, recruitment commenced in October 2025 and is ongoing. As of July 2026, 20 participants have been enrolled. Study completion is anticipated in August 2028. Conclusions: This trial will determine the feasibility and acceptability of WISH 2.0, a novel PP intervention for IBS. Comparative results between WISH 2.0 and an educational control, including the possibility of equivalent outcomes, will provide important mechanistic insights and facilitate further optimization of BGBTs for IBS, informing a future fully powered efficacy trial.
- 23 July 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e98352
Open AccessThe WISH 2.0 Intervention for Irritable Bowel Syndrome: Protocol for a Pilot Randomized Controlled Trial
Background: There is a critical need for acceptable, scalable, and mechanistically targeted behavioral health interventions for irritable bowel syndrome (IBS), known as brain-gut behavior therapies (BGBTs). Although positive psychology (PP) interventions, which focus on the cultivation of positive psychological well-being, have been linked to improved health outcomes across diverse medical populations, they have not yet been investigated in IBS. To address this gap, we developed WISH (Well-Being in IBS: Strengths and Happiness), a novel, 9-week, phone-delivered PP-based BGBT for individuals with IBS. Objective: This randomized controlled trial (RCT) aims to evaluate the feasibility, acceptability, preliminary effects, and candidate gut-brain mechanisms of a 9-week phone-delivered PP intervention for IBS compared with a time- and attention-matched educational control. Methods: The WISH 2.0 trial is a parallel-group, 9-week pilot RCT that aims to enroll 50 adults meeting Rome IV criteria for IBS. Participants are randomized (1:1), stratified by IBS subtype and gender, to either the WISH 2.0 intervention or an educational control condition. Both conditions consist of 9 weekly 30-minute phone sessions accompanied by weekly manualized exercises. Primary outcomes are feasibility (proportion completing ≥6 of 9 sessions) and acceptability (weekly ease and utility ratings). Secondary outcomes include WISH 2.0’s preliminary effects on health-related, health behavior, and psychological outcomes, assessed at 4 time points: baseline, intervention midpoint, the postintervention assessment, and the 3-month postintervention assessment. Candidate gut-brain mechanisms that might underlie WISH 2.0’s effects, including changes in autonomic function (heart rate variability), interoception (self-report measure), gene expression (whole transcriptome RNA sequencing), and immune system activity (serum inflammatory biomarkers), will be explored before and after the intervention. Results: The trial was approved by the Mass General Brigham Institutional Review Board and prospectively registered at ClinicalTrials.gov in March 2025. Funding was awarded in June 2025. Following a study start-up period, recruitment commenced in October 2025 and is ongoing. As of July 2026, 20 participants have been enrolled. Study completion is anticipated in August 2028. Conclusions: This trial will determine the feasibility and acceptability of WISH 2.0, a novel PP intervention for IBS. Comparative results between WISH 2.0 and an educational control, including the possibility of equivalent outcomes, will provide important mechanistic insights and facilitate further optimization of BGBTs for IBS, informing a future fully powered efficacy trial.
- Open Access
- 12 July 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (5) , 574-589
Meta‐Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers–Danlos Syndrome and Hypermobility Spectrum Disorders
Background: Patients with Ehlers–Danlos syndrome (EDS)/hypermobility spectrum disorders (HSD) report higher rates of chronic gastrointestinal (GI) symptoms, disorders of gut–brain interaction (DGBI), and extraintestinal comorbidities. Aims: We conducted a systematic review and meta‐analysis to assess the prevalence of chronic GI symptoms and comorbid conditions in hEDS/HSD. Methods: Electronic databases were searched until December 2025 for studies reporting on chronic GI symptoms in hEDS/HSD patients. Pooled prevalence rates, odds ratios (ORs), and 95% confidence intervals (CIs) were calculated using the random effects model. Results: The final dataset of 19 studies included 17,455 hEDS/HSD patients and 1,677,465 controls. The odds of chronic GI symptoms were higher in patients with hEDS/HSD compared to controls (OR 4.29, 95% CI 3.1–6.0). 65.3% (95% CI 51.4–77.0) of hEDS/HSD patients reported at least one chronic GI symptom, with heartburn being the most common (34.7%, 95% CI 28.3–41.7). The prevalence of DGBI in hEDS/HSD patients was 44.2% (95% CI 23.9–66.6), with functional dysphagia the most common DGBI at 34.2% (95% CI 25.7–43.8). Gastroesophageal reflux disease was reported in 41.3% (95% CI 27.2–57.0). In hEDS/HSD patients, the most common extraintestinal comorbidity was chronic fatigue (49%, 95% CI 34.6–63.6), followed by migraine (38.2%, 95% CI 19.9–60.5), orthostatic intolerance (OI) (35.9%, 95% CI 26.6–46.4), fibromyalgia (27.9%, 95% CI 16.0–44.0) and postural orthostatic tachycardia syndrome (POTS) (21.9%, 95% CI 5.2–59.1). Conclusions: Overall, > 60% of hEDS/HSD patients report chronic GI symptoms. DGBI, co‐morbidities, including POTS, were highly prevalent in hEDS/HSD patients. However, the quality of the evidence is low due to significant clinical heterogeneity observed in the analyses. While the associations may suggest a causal relationship, the results should be interpreted with caution.
- 12 July 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 64 (5) , 574-589
Open AccessMeta‐Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers–Danlos Syndrome and Hypermobility Spectrum Disorders
Background: Patients with Ehlers–Danlos syndrome (EDS)/hypermobility spectrum disorders (HSD) report higher rates of chronic gastrointestinal (GI) symptoms, disorders of gut–brain interaction (DGBI), and extraintestinal comorbidities. Aims: We conducted a systematic review and meta‐analysis to assess the prevalence of chronic GI symptoms and comorbid conditions in hEDS/HSD. Methods: Electronic databases were searched until December 2025 for studies reporting on chronic GI symptoms in hEDS/HSD patients. Pooled prevalence rates, odds ratios (ORs), and 95% confidence intervals (CIs) were calculated using the random effects model. Results: The final dataset of 19 studies included 17,455 hEDS/HSD patients and 1,677,465 controls. The odds of chronic GI symptoms were higher in patients with hEDS/HSD compared to controls (OR 4.29, 95% CI 3.1–6.0). 65.3% (95% CI 51.4–77.0) of hEDS/HSD patients reported at least one chronic GI symptom, with heartburn being the most common (34.7%, 95% CI 28.3–41.7). The prevalence of DGBI in hEDS/HSD patients was 44.2% (95% CI 23.9–66.6), with functional dysphagia the most common DGBI at 34.2% (95% CI 25.7–43.8). Gastroesophageal reflux disease was reported in 41.3% (95% CI 27.2–57.0). In hEDS/HSD patients, the most common extraintestinal comorbidity was chronic fatigue (49%, 95% CI 34.6–63.6), followed by migraine (38.2%, 95% CI 19.9–60.5), orthostatic intolerance (OI) (35.9%, 95% CI 26.6–46.4), fibromyalgia (27.9%, 95% CI 16.0–44.0) and postural orthostatic tachycardia syndrome (POTS) (21.9%, 95% CI 5.2–59.1). Conclusions: Overall, > 60% of hEDS/HSD patients report chronic GI symptoms. DGBI, co‐morbidities, including POTS, were highly prevalent in hEDS/HSD patients. However, the quality of the evidence is low due to significant clinical heterogeneity observed in the analyses. While the associations may suggest a causal relationship, the results should be interpreted with caution.
- Open Access
- 25 June 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (6) , e70385
Editorial: Bodily Maps of Emotions in Irritable Bowel Syndrome—Implications for Brain–Gut and Gut–Brain Interventions
- 25 June 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (6) , e70385
Open AccessEditorial: Bodily Maps of Emotions in Irritable Bowel Syndrome—Implications for Brain–Gut and Gut–Brain Interventions
- 22 May 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (9) , 2169-2181
A phase 2 multicenter, prospective, randomized, double-blind study to assess the clinical and antiviral efficacy and safety of nitazoxanide for the treatment of norovirus in hematopoietic stem cell and solid organ transplant recipients
- 22 May 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (9) , 2169-2181
A phase 2 multicenter, prospective, randomized, double-blind study to assess the clinical and antiviral efficacy and safety of nitazoxanide for the treatment of norovirus in hematopoietic stem cell and solid organ transplant recipients
- Open Access
- 8 April 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (4) , e70305
Gastrointestinal Symptoms and Systemic Comorbidities in Patients With POTS : A Systematic Review and Meta‐Analysis
Background: Patients with postural orthostatic tachycardia syndrome (POTS) frequently report higher rates of chronic gastrointestinal symptoms, disorders of gut‐brain interaction (DGBI), and extra‐intestinal co‐morbidities. We conducted a systematic review and meta‐analysis to assess the prevalence of gastrointestinal symptoms and comorbid conditions in POTS patients. Methods: Electronic databases were searched from inception until May 2025 for studies reporting gastrointestinal symptoms in POTS patients. A random‐effects model was used to pool the proportion of POTS patients reporting gastrointestinal symptoms, and sub‐group analyses were conducted. Results: The final dataset includes 19 studies, with 8268 POTS patients, revealing that 57.9% (95% CI 38.4–75.2) had at least one gastrointestinal symptom. The most common gastrointestinal symptom was nausea (70.1%, 95% CI 51.5–83.7) followed by bloating (64.9%, 95% CI 48.5–78.4), abdominal pain (60.4%, 95% CI 39.2–78.3) and postprandial fullness (60.4%, 95% CI 45.6–73.6). Irritable bowel syndrome was the most prevalent DGBI, affecting 26.8% (95% CI 15.3–42.4) of POTS patients. The most common extraintestinal comorbidity was anxiety, reported in 42.9% (95% CI 22.7–65.8), followed by chronic fatigue (40.9%, 95% CI 21.1–64.2), migraine (35.6%, 95% CI 27.0–45.2), depression (34.4%, 95% CI 19.0–54.0), and fibromyalgia (21.6%, 95% CI 12.8–34.2). Approximately one third reported mast cell activation syndrome (36.3%, 95% CI 17.8–60.0) and joint hypermobility syndrome (31%, 95% CI 24.4–38.5). There was substantial heterogeneity seen in the primary and most subgroup analyses. Conclusions: Overall, 60% of POTS patients report concurrent gastrointestinal symptoms, with nausea being the most common. IBS affects 25% of patients with POTS. Notably, extra‐intestinal comorbidities—primarily anxiety, chronic fatigue, migraines, depression, and fibromyalgia—are more prevalent than gastrointestinal conditions in this population.
- 8 April 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (4) , e70305
Open AccessGastrointestinal Symptoms and Systemic Comorbidities in Patients With POTS : A Systematic Review and Meta‐Analysis
Background: Patients with postural orthostatic tachycardia syndrome (POTS) frequently report higher rates of chronic gastrointestinal symptoms, disorders of gut‐brain interaction (DGBI), and extra‐intestinal co‐morbidities. We conducted a systematic review and meta‐analysis to assess the prevalence of gastrointestinal symptoms and comorbid conditions in POTS patients. Methods: Electronic databases were searched from inception until May 2025 for studies reporting gastrointestinal symptoms in POTS patients. A random‐effects model was used to pool the proportion of POTS patients reporting gastrointestinal symptoms, and sub‐group analyses were conducted. Results: The final dataset includes 19 studies, with 8268 POTS patients, revealing that 57.9% (95% CI 38.4–75.2) had at least one gastrointestinal symptom. The most common gastrointestinal symptom was nausea (70.1%, 95% CI 51.5–83.7) followed by bloating (64.9%, 95% CI 48.5–78.4), abdominal pain (60.4%, 95% CI 39.2–78.3) and postprandial fullness (60.4%, 95% CI 45.6–73.6). Irritable bowel syndrome was the most prevalent DGBI, affecting 26.8% (95% CI 15.3–42.4) of POTS patients. The most common extraintestinal comorbidity was anxiety, reported in 42.9% (95% CI 22.7–65.8), followed by chronic fatigue (40.9%, 95% CI 21.1–64.2), migraine (35.6%, 95% CI 27.0–45.2), depression (34.4%, 95% CI 19.0–54.0), and fibromyalgia (21.6%, 95% CI 12.8–34.2). Approximately one third reported mast cell activation syndrome (36.3%, 95% CI 17.8–60.0) and joint hypermobility syndrome (31%, 95% CI 24.4–38.5). There was substantial heterogeneity seen in the primary and most subgroup analyses. Conclusions: Overall, 60% of POTS patients report concurrent gastrointestinal symptoms, with nausea being the most common. IBS affects 25% of patients with POTS. Notably, extra‐intestinal comorbidities—primarily anxiety, chronic fatigue, migraines, depression, and fibromyalgia—are more prevalent than gastrointestinal conditions in this population.
- 7 April 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (4) , e70313
A Primer for Discussing Complementary and Integrative Medicine in Gastroenterology Settings
Background: Complementary and integrative medicine interventions have been increasingly utilized among patients with chronic gastrointestinal disorders. However, to date, there is no data on the implementation of these approaches as part of gastroenterology consultations and follow‐up visits, which suggests that gastroenterology professionals may need more guidance on how to routinely engage in discussions about complementary and integrative medicine approaches to promote best practice. Purpose: This article aims to provide practical recommendations for gastroenterology professionals on how to initiate and navigate discussions about the use of complementary and integrative medicine interventions for patients in routine GI practice settings.
- 7 April 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (4) , e70313
A Primer for Discussing Complementary and Integrative Medicine in Gastroenterology Settings
Background: Complementary and integrative medicine interventions have been increasingly utilized among patients with chronic gastrointestinal disorders. However, to date, there is no data on the implementation of these approaches as part of gastroenterology consultations and follow‐up visits, which suggests that gastroenterology professionals may need more guidance on how to routinely engage in discussions about complementary and integrative medicine approaches to promote best practice. Purpose: This article aims to provide practical recommendations for gastroenterology professionals on how to initiate and navigate discussions about the use of complementary and integrative medicine interventions for patients in routine GI practice settings.
- 28 February 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (6) , 1183-1191
Model psychosocial care for youth with inflammatory bowel disease
Background: Youth with inflammatory bowel diseases (IBDs) are at an increased risk for mental health concerns compared to healthy peers. Given the unique psychosocial risk factors involved in living with IBD, it can be challenging to identify what level of psychological support is needed, which professionals may be best suited to intervene, and what setting would be appropriate. Methods: In this narrative review we have applied the pediatric psychosocial preventative health model (PPPHM) to pediatric IBD by delineating 3 tiers of psychosocial need and associated evidence-based psychological interventions. Results: The PPPHM describes universal, targeted, and clinical/treatment psychosocial needs. All youth with IBD benefit from universal support, such as psychosocial screening, education, and social support. As psychosocial needs are identified, providers may consider whether they need targeted or clinical/treatment levels of care. Targeted needs may include general mental health concerns (eg, grief), and psychosocial concerns related to their IBD that could benefit from psychological consultation or brief interventions (eg, pill swallowing). For young people with psychosocial concerns that are associated with significant distress or impairment, higher levels of psychological care, including outpatient referrals, may be beneficial. Conclusions: Ultimately, identification of the intensity of psychosocial needs and associated appropriate levels of intervention for youth with IBD can be challenging to ascertain. However, with this review we hope to simplify that process so IBD providers with a variety of professional backgrounds and resources can help assess and connect patients with the appropriate support.
- 28 February 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (6) , 1183-1191
Model psychosocial care for youth with inflammatory bowel disease
Background: Youth with inflammatory bowel diseases (IBDs) are at an increased risk for mental health concerns compared to healthy peers. Given the unique psychosocial risk factors involved in living with IBD, it can be challenging to identify what level of psychological support is needed, which professionals may be best suited to intervene, and what setting would be appropriate. Methods: In this narrative review we have applied the pediatric psychosocial preventative health model (PPPHM) to pediatric IBD by delineating 3 tiers of psychosocial need and associated evidence-based psychological interventions. Results: The PPPHM describes universal, targeted, and clinical/treatment psychosocial needs. All youth with IBD benefit from universal support, such as psychosocial screening, education, and social support. As psychosocial needs are identified, providers may consider whether they need targeted or clinical/treatment levels of care. Targeted needs may include general mental health concerns (eg, grief), and psychosocial concerns related to their IBD that could benefit from psychological consultation or brief interventions (eg, pill swallowing). For young people with psychosocial concerns that are associated with significant distress or impairment, higher levels of psychological care, including outpatient referrals, may be beneficial. Conclusions: Ultimately, identification of the intensity of psychosocial needs and associated appropriate levels of intervention for youth with IBD can be challenging to ascertain. However, with this review we hope to simplify that process so IBD providers with a variety of professional backgrounds and resources can help assess and connect patients with the appropriate support.
- 20 November 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 160, 108151
Combination Therapy of Resilience Intervention with Biologics in Crohn's Disease (CATHARSIS): Study protocol for a randomized controlled trial
- 20 November 2025
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 160, 108151
Combination Therapy of Resilience Intervention with Biologics in Crohn's Disease (CATHARSIS): Study protocol for a randomized controlled trial